Kiromic BioPharma Statistics
Share Statistics
Kiromic BioPharma has 1.55M shares outstanding. The number of shares has increased by 31.43% in one year.
| Shares Outstanding | 1.55M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.23% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.13M |
| Failed to Deliver (FTD) Shares | 659 |
| FTD / Avg. Volume | 51.77% |
Short Selling Information
The latest short interest is 45.74K, so 2.96% of the outstanding shares have been sold short.
| Short Interest | 45.74K |
| Short % of Shares Out | 2.96% |
| Short % of Float | 4.06% |
| Short Ratio (days to cover) | 1.45 |
Valuation Ratios
The PE ratio is -0.04 and the forward PE ratio is -0.63.
| PE Ratio | -0.04 |
| Forward PE | -0.63 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -0.1 |
| P/FCF Ratio | -0.04 |
| PEG Ratio | n/a |
Enterprise Valuation
Kiromic BioPharma Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 0.22, with a Debt / Equity ratio of -1.53.
| Current Ratio | 0.22 |
| Quick Ratio | 0.22 |
| Debt / Equity | -1.53 |
| Total Debt / Capitalization | 286.93 |
| Cash Flow / Debt | -1.52 |
| Interest Coverage | 10.77 |
Financial Efficiency
Return on equity (ROE) is 2.33% and return on capital (ROIC) is -310.5%.
| Return on Equity (ROE) | 2.33% |
| Return on Assets (ROA) | -1.75% |
| Return on Capital (ROIC) | -310.5% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -608.40K |
| Employee Count | 35 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 245.45% in the last 52 weeks. The beta is 1.98, so Kiromic BioPharma 's price volatility has been higher than the market average.
| Beta | 1.98 |
| 52-Week Price Change | 245.45% |
| 50-Day Moving Average | 1.03 |
| 200-Day Moving Average | 2 |
| Relative Strength Index (RSI) | 45.96 |
| Average Volume (20 Days) | 1.27K |
Income Statement
In the last 12 months, Kiromic BioPharma had revenue of $0 and earned -$21.29M in profits. Earnings per share was $-21.41.
| Revenue | 0 |
| Gross Profit | -2.80M |
| Operating Income | -19.94M |
| Net Income | -21.29M |
| EBITDA | -16.30M |
| EBIT | - |
| Earnings Per Share (EPS) | -21.41 |
Balance Sheet
The company has $3.20M in cash and $15.54M in debt, giving a net cash position of -$12.34M.
| Cash & Cash Equivalents | 3.20M |
| Total Debt | 15.54M |
| Net Cash | -12.34M |
| Retained Earnings | -122.90M |
| Total Assets | 10.24M |
| Working Capital | -14.83M |
Cash Flow
In the last 12 months, operating cash flow was -$21.23M and capital expenditures -$206.60K, giving a free cash flow of -$21.43M.
| Operating Cash Flow | -21.23M |
| Capital Expenditures | -206.60K |
| Free Cash Flow | -21.43M |
| FCF Per Share | -19.53 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
KRBP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -2253.68% |
| FCF Yield | -1459.32% |
Analyst Forecast
Currently there are no analyst rating for KRBP.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Mar 13, 2023. It was a backward split with a ratio of 1:30.
| Last Split Date | Mar 13, 2023 |
| Split Type | backward |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | -28.19 |
| Piotroski F-Score | 1 |